Arena Pharmaceuticals' Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community

Rhea-AI Summary

Arena Pharmaceuticals (ARNA) announced its participation in the 26th Annual United European Gastroenterology (UEG) Week, scheduled for October 11-13, 2020. The company will present new data from its Phase 2 OASIS trial for etrasimod, focused on ulcerative colitis, along with preclinical data for olorinab, targeting gastrointestinal pain. Key presentations include a symposium on investigational treatments and detailed findings from clinical trials. Both drugs remain investigational and are not approved for use.

Positive

• Presentation of Phase 2 OASIS trial data for etrasimod, demonstrating progress in ulcerative colitis treatment.
• Preclinical data for olorinab shows potential for treating visceral pain in gastrointestinal conditions.
• Participation in UEG Week highlights commitment to advancing gastrointestinal disease treatment.

Negative

• Etrasimod and olorinab are still investigational and not approved for any use, indicating ongoing risk in development.

SAN DIEGO, Oct. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new data from the Phase 2 OASIS trial and its open-label extension for its investigative drug candidate etrasimod, a next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator, in patients with moderately to severely active ulcerative colitis (UC) at the 26th Annual United European Gastroenterology (UEG) Week. Arena will also present preclinical data for olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB₂), in development for the treatment of visceral pain in gastrointestinal (GI) diseases. UEG Week is taking place virtually October 11-13, 2020.

Arena Sponsored Symposium Details: 
Title: Opening the Door to Emerging Investigational Treatments in Ulcerative Colitis: What Awaits Us?
Intended Audience: This symposium is designed for non-US healthcare professionals and is not affiliated with UEGW
Speakers: William Sandborn, MD (Chair), Professor Silvio Danese, Remo Panaccione, MD, FRCPC
Day/Time: Monday, October 12 at 17:30 CET

Presentation Details:
Title: Early and Durable Symptom Control in Patients with Moderately to Severely Active Ulcerative Colitis Treated with Etrasimod in the Randomised, Double Blind, Placebo Controlled, Phase 2 OASIS Trial and Open Label Extension
Day/Time: Tuesday, October 13, 2020, from 15:00-16:00 CET
ePoster: P0481

Title: Expression of Cannabinoid Receptors and the Effect of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, on Visceral Hypersensitivity in Rodent Models of Irritable Bowel Syndrome and Inflammatory Bowel Disease 
Day/Time: Sunday, October 11, 2020, 18:00-19:00 CET    
Oral presentation: OP058    

Title: The Incremental Increasing Rate of Thromboembolic Events in Patients with Inflammatory Bowel Disease Compared to Patients Without Autoimmune Disorder   
Event: Virtual poster exhibition
ePoster: P0377                    

About Etrasimod
Etrasimod (APD334) is a once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator, discovered by Arena, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes 1, 4 and 5. Etrasimod has therapeutic potential in immune and inflammatory-mediated diseases such as ulcerative colitis, Crohn's disease, and atopic dermatitis. S1P receptors have been demonstrated to be involved in the modulation of several biological responses, including lymphocyte trafficking from lymph nodes to the peripheral blood. By isolating subpopulations of lymphocytes in lymph nodes, fewer immune cells are available in the circulating blood to effect tissue damage.

About Olorinab
Olorinab (APD371) is an oral, peripherally acting, highly selective, full agonist of the cannabinoid type 2 receptor (CB₂). Olorinab is an internally discovered investigational drug candidate that Arena is exploring for development in several indications, with an initial focus on visceral pain in gastrointestinal disorders. This compound, through its selectivity for CB₂, versus the cannabinoid type 1 receptor (CB₁), was designed to provide pain relief while minimizing the risk of psychoactive adverse effects.

Etrasimod and olorinab are investigational compounds that are not approved for any use in any country.

About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a singular purpose – deliver our important medicines to patients.

In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get our medicines to patients, and relentlessly execute until it's done.

ARENA - Care More. Act Differently.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's participation in UEG Week, including its symposium, and data presentations; the opportunity, development and potential of etrasimod and olorinab; and Arena's purpose, work, understanding, ideas, and execution. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Corporate Contact:
Megan E. Knight
Arena Pharmaceuticals, Inc.
Director, Investor Relations 
mknight@arenapharm.com 
858.210.3635

Arena Media Contact: 
IR@arenapharm.com 
858.453.7200 

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-presence-at-united-european-gastroenterology-week-strengthens-ongoing-commitment-to-the-gastrointestinal-disease-community-301149612.html

SOURCE Arena Pharmaceuticals, Inc.

FAQ

What is the significance of the Phase 2 OASIS trial data for etrasimod presented by Arena Pharmaceuticals?

The Phase 2 OASIS trial data for etrasimod highlights its potential effectiveness in treating moderately to severely active ulcerative colitis, indicating advancement in the drug's clinical development.

When is Arena Pharmaceuticals presenting at UEG Week?

Arena Pharmaceuticals will present its findings at the 26th Annual United European Gastroenterology Week from October 11-13, 2020.

What are the investigational drugs being showcased by Arena Pharmaceuticals?

Arena Pharmaceuticals is showcasing etrasimod, a treatment for ulcerative colitis, and olorinab, aimed at managing visceral pain in gastrointestinal diseases.

Is etrasimod approved for use?

No, etrasimod is an investigational compound and is not approved for any use in any country.

What type of presentation will Arena Pharmaceuticals conduct at UEG Week?

Arena Pharmaceuticals will conduct a symposium and multiple presentations, including findings from the Phase 2 OASIS trial and preclinical data on olorinab.